地球を汚染する過フッ素化合物類
第7部 デュポン社の PFOA についての言い訳
引用情報・文献
[1] DuPont (2003). March 18, 2003 DuPont media briefing presentation by Paul Bossert, plant manager of DuPont Washington Works.
[2] West Virginia Department of Environmental Protection (WVDEP) (2002). Press Release: Health Level for C8 announced by expert team.
[3] Hilderliter, PM and Jepson, GW. 2001. A simple, conservative compartmental model to relate ammonium perfluorooctanoate (APFO) exposure estimates of perfluorooctanoate (PFO) blood levels in humans. DuPont Haskell Laboratory for Health and Enviornmental Sciences.
[4] York, RG (2002). Oral (gavage) two-generation (one litter per generation) reproduction study of ammonium perfluorooctanoate (APFO) in rats. Report prepared for 3M, St. Paul, MN by Argus Research (Horsham, PA). Sponsor's Study No. T-6889.6., US EPA Adminstrative Record AR226-1092, Reviewed in US EPA Adminstrative Record AR226-1137 (pages 282-295; PDF pages 179-191).
[5] Fayerweather, WE. 1981. Liver study of Washington Works employees exposed to C-8: results of blood chemistry testing (not published).
[6] DuPont. 1979. Personal and confidential memo from Dr. Fayerweather (epidemiologis) to Dr. Power (medical superintendent): Status report on Washington Works liver function survey and coronary heart disease mortality study - August 28. 1979.
[7] Alexander, B (2001). Mortality study of workers employed at the 3M Cottage Grove facility. Final Report. Division of Environmental and Occupational Health, School of Public Health, University of Minnesota, April 26, 2001, Reviewed in U.S. EPA Administrative Record AR226-1137 (pages 143-146; PDF pages 40-43).
[8] Gilliland, FD and Mandel, JS. 1993. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med 35(9): 950-4. Also reviewed in EPA Administrative Record document AR226-1137 (pages 140-42; PDF pages 37-39).
[9] Sibinski, LJ. 1987. Two-Year oral (diet) toxicity/carcinogenicity study of fluorochemical FC-143 (perfluorooctane ammonium carboxylate) in rats. Report prepared for 3M, St. Paul, Minnesota by Riker Laboratories Inc. Study No. 0281CR0012; 8EHQ-1087-0394, October 16, 1987 Reviewed in US EPA "Revised Draft PFOA Hazard Assessment-Robust Study Annex" AR226-1137, (pp. 260-267; PDF pp 157-164).
[10] Biegel, LB., Hurtt, ME., Frame, SR., O'Connor, JC and Cook, JC. 2001. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci 60(1): 44-55.
[11] Alexander, B (2001b). Mortality study of workers employed at the 3M Decatur facility. Final Report. Division of Environmental and Occupational Health, School of Public Health, University of Minnesota, April 26, 2001, Reviewed in “Letter from Mr. Charles Auer and Draft Hazard Assessment of PFOA and its Salts with Page 8 was corrected on 4/15/02” U.S. EPA Administrative Record AR226-1093.
[12] Olsen, GW., Burlew, MM., Hocking, BB., Skratt, JC., Burris, JM and Mandel, JH. 2001. An epidemiologic analysis of episodes of care of 3M Decatur chemical and film plant employees, 1993-1998. Reviewed in US Environmental Protection Agency Administrative Record AR226-1137 (pages 156-159; PDF pages 53-56).
[13] Ries, LAG., Eisner, MP., Kosary, CL., Hankey, BF., Miller, BA., Clegg, L and Edwards, BK. 2002. SEER Cancer Statistics Review 1973-1999: Overview in a Single PDF. National Cancer Institute. Bethesda, MD. Available online at http://seer.cancer.gov/csr/1973_1999/sections.html.
[14] Ries, LAG., Eisner, MP., Kosary, CL., Hankey, BF., Miller, BA., Clegg, L and Edwards, BK. 2002. SEER Cancer Statistics Review 1973-1999: Childhood Cancer by the International Classification of Childhood Cancer (ICCC). National Cancer Institute. Bethesda, MD. Available online at http://seer.cancer.gov/csr/1973_1999/sections.html.
[15] Ries, LAG., Eisner, MP., Kosary, CL., Hankey, BF., Miller, BA., Clegg, L and Edwards, BK. 2002. SEER Cancer Statistics Review 1973-1999: Sections of the CSR, 1973-1999, Testis. National Cancer Institute. Bethesda, MD. Available online at http://seer.cancer.gov/csr/1973_1999/sections.html.
[16] Environmental Protection Agency (EPA). 2003. Draft final guidelines for carcinogen risk assessment (external review draft, February 2003). Available online at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=55445.
[17] DuPont Haskell Laboratory. 2002. Developmental and one-generation reproduction study: Mixture of poly(difluoro-methylene), alpha-fluoro-omega [2-(phosphonooxy) ethyl]-, monoammonium salt (CAS# 65530-71-4); poly(difluoro-methylene), alpha-fluoro-omega[2-(phosphonooxy) ethyl]-, diammonium salt (CAS# 65530-72-5); poly(difluoromethylene), alpha, alpha’- [phosphinicobis(oxy-2,1-ethanediyl)bis [omega-fluoro-], ammonium salt (CAS# 65530-70-3); isopropyl alcohol (CAS# 67-63-0); and water (CAS# 7732-18-5). US Environmental Protection Agency: Toxic Substance Control Act (TSCA) Section 8(e) Submission Received from 01/02/03 to 1/15/03: 8EHQ-1202-15247A. December 20, 2002. Available online at http://www.epa.gov/opptintr/tsca8e/doc/new8e.htm.
[18] DuPont Haskell Laboratory. 2002. Subchronic toxicity study: Mixture of poly(difluoro-methylene), alpha-fluoro-omega [2-(phosphonooxy) ethyl]-, monoammonium salt (CAS# 65530-71-4); poly(difluoro-methylene), alpha-fluoro-omega[2-(phosphonooxy) ethyl]-, diammonium salt (CAS# 65530-72-5); poly(difluoromethylene), alpha, alpha’- [phosphinicobis(oxy-2,1-ethanediyl)bis [omega-fluoro-], ammonium salt (CAS# 65530-70-3); isopropyl alcohol (CAS# 67-63-0); and water (CAS# 7732-18-5) (Telomer B Phoshate). US Environmental Protection Agency: Toxic Substance Control Act (TSCA) Section 8(e) Submission Received from 02/27/02 thru 03/13/02: 8EHQ-0202-15072A. February 6, 2002. Available online at http://www.epa.gov/oppt/tsca8e/doc/8esub/8e031302.htm.
[19] DuPont. 2002. The updated copy of DuPont Product Stewardship on December 17, 2001. U.S. EPA Administrative Record AR226-1069.
[20] DuPont Haskell Laboratory. 2002. Results of an oral gavage combined 90-day repeated dose and one-generation reproductive toxicity study in rats for poly (oxy-1,2-ethanediyl) alpha-hydro-omega-hydroxy- ether, with alpha-fluoro- omega (2-hydroxyethyl) poly (difluoromethane) (1:1) (telomer B monoether)(CAS Number 65545-80-4; non-HPV). US Environmental Protection Agency: Toxic Substance Control Act (TSCA) Section 8(e) Submission Received from 10/15/01 thru 12/07/01: 8EHQ-1001-14915. November 5, 2001. Available online at http://www.epa.gov/opptintr/tsca8e/doc/8esub/8e101501.htm.
[21] DuPont. 2002. DuPont flurotelomer product stewardship update, presented November 25, 2002. U.S. EPA Administrative Record AR226-1147.
[22] Hill, RN., Crisp, TM., Hurley, PM., Rosenthal, SL and Singh, DV. 1998. Risk assessment of thyroid follicular cell tumors. Environ Health Perspect 106(8): 447-57.
[23] Hurley, PM. 1998. Mode of carcinogenic action of pesticides inducing thyroid follicular cell tumors in rodents. Environ Health Perspect 106(8): 437-45.
[24] Olsen, GW., Burlew, MM., Burris, JM and Mandel, JH (2001). Final report: A longitudinal analysis of serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) levels in relation to lipid and hepatic clinical chemistry test results from male employee participants of the 1994/95, 1997, and 2000 fluorochemical medical surveillance program, 3M Medical Department, Epidimiology 220-3W-05.
[25] Olsen, GW., Burlew, MM., Burris, JM and Mandel, JH (2001). Final report: A cross-sectional analysis of serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to clinical chemistry, thyroid hormone, hematoloty and urinalysis results from male and female employee participants of the 2000 Antwerp and Decatur fluorochemical medical surveillance program, 3M Medical Department, Epidimiology 220-3W-05.
[26] Olsen, GW., Gilliland, FD., Burlew, MM., Burris, JM., Mandel, JS and Mandel, JH. 1998. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med 40(7): 614-22. Also reviewed in U.S. EPA Administrative Record AR226-1137 (pages 147-149; PDF pages 44-46).
[27] Biegel, LB., Liu, RC., Hurtt, ME and Cook, JC. 1995. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol 134(1): 18-25.
[28] vom Saal, FS., Timms, BG., Montano, MM., Palanza, P., Thayer, KA., Nagel, SC., Dhar, MD., Ganjam, VK., Parmigiani, S and Welshons, WV. 1997. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci U S A 94(5): 2056-61.
[29] DuPont (1997). Hazard characterization for human health C8 exposure CAS registry no. 3825-26-1. Prepared by L.B. Biegel, Senior Research Toxicologist.
[30] Hollowell, JG., Staehling, NW., Flanders, WD., Hannon, WH., Gunter, EW., Spencer, CA and Braverman, LE. 2002. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87(2): 489-99.
[31] Haddow, JE., Palomaki, GE., Allan, WC., Williams, JR., Knight, GJ., Gagnon, J., O'Heir, CE., Mitchell, ML., Hermos, RJ., Waisbren, SE., Faix, JD and Klein, RZ. 1999. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341(8): 549-55.
[32] Upham, BL., Deocampo, ND., Wurl, B and Trosko, JE. 1998. Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. Int J Cancer 78(4): 491-5.
[33] Liu, RC., Hurtt, ME., Cook, JC and Biegel, LB. 1996. Effect of the peroxisome proliferator, ammonium perfluorooctanoate (C8), on hepatic aromatase activity in adult male Crl:CD BR (CD) rats. Fundam Appl Toxicol 30(2): 220-8.
[34] National Toxicology Program (NTP). 2002. 10th Report on Carcinogens. Available online at http://ehp.niehs.nih.gov/roc/toc10.html.
[35] Environmental Protection Agency (EPA). 2002. Revised draft hazard assessment of perfluorooctanoic acid and its salts, November 4, 2002. U.S. EPA Administrative Record AR226-1136.
[36] Thayer, KA., Ruhlen, RL., Howdeshell, KL., Buchanan, DL., Cooke, PS., Preziosi, D., Welshons, WV., Haseman, J and vom Saal, FS. 2001. Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol. Hum Reprod 16(5): 988-96.
[37] Environmental Protection Agency (EPA). 2003. Preliminary risk assessment of the developmental toxicity associated with exposure to perfluorooctanoic acid and its salts. March 17, 2003.
[38] Godfrey, KM and Barker, DJ. 2001. Fetal programming and adult health. Public Health Nutr 4(2B): 611-24.
[39] Hales, CN and Barker, DJ. 2001. The thrifty phenotype hypothesis. Br Med Bull 60: 5-20.
[40] Eriksson, J., Forsen, T., Tuomilehto, J., Osmond, C and Barker, D. 2000. Fetal and childhood growth and hypertension in adult life. Hypertension 36(5): 790-4.
[41] Eriksson, JG., Forsen, T., Tuomilehto, J., Jaddoe, VW., Osmond, C and Barker, DJ. 2002. Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals. Diabetologia 45(3): 342-8.
[42] Eriksson, JG., Forsen, T., Tuomilehto, J., Osmond, C and Barker, DJ. 2000. Early growth, adult income, and risk of stroke. Stroke 31(4): 869-74.
[43] Eriksson, JG., Forsen, T., Tuomilehto, J., Winter, PD., Osmond, C and Barker, DJ. 1999. Catch-up growth in childhood and death from coronary heart disease: longitudinal study. Bmj 318(7181): 427-31.
[44] Eriksson, JG and Forsen, TJ. 2002. Childhood growth and coronary heart disease in later life. Ann Med 34(3): 157-61.
[45] Ong, KK and Dunger, DB. 2002. Perinatal growth failure: the road to obesity, insulin resistance and cardiovascular disease in adults. Best Pract Res Clin Endocrinol Metab 16(2): 191-207.
[46] Stettler, N., Bovet, P., Shamlaye, H., Zemel, BS., Stallings, VA and Paccaud, F. 2002. Prevalence and risk factors for overweight and obesity in children from Seychelles, a country in rapid transition: the importance of early growth. Int J Obes Relat Metab Disord 26(2): 214-9.
[47] Palazzolo, M (1993). 13-week dietary toxicity study with T-5180, ammonium perfluorooctanoate (CAS N. 3826-1) in male rats. Report prepared for 3M, St. Paul, MN, Reviewed in US EPA "Draft PFOA Hazard Assessment" AR226-1079.
[48] Cook, JC., Murray, SM., Frame, SR and Hurtt, ME. 1992. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol 113(2): 209-17.
[49] Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G, Jr.., Lieder, P., Olsen, G and Thomford, P. 2002. Toxicity of Ammonium Perfluorooctanoate in Male Cynomolgus Monkeys after Oral Dosing for 6 Months. Toxicol Sci 69(1): 244-257. Also reviewed in US EPA Reviewed in US EPA "Revised Draft PFOA Hazard Assessment-Robust Study Annex" AR226-1137, p. 244-253.
[50] Goldenthal, EI., Jessup, DC., Geil, RG and Mehring, JS. 1978. Ninety-day subacute rhesus monkey toxicity study: Fluorad ¨ Fluorochemical FC-143. Report prepared for 3M, St. Paul, MN by Institutional Research and Devlopment Corporation (Mattawan, MN). Study No. 137-090. Reviewed in US EPA "Draft PFOA Hazard Assessment" AR226-1079.
[51] Derelanko, MJ. 2000. Toxicologist Pocket HandbookWashington DC, CRC Press.
[52] Gilliland, FD and Mandel, JS. 1996. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am J Ind Med 29(5): 560-8. Reviewed in US Environmental Protection Agency Administrative Record AR226-1137 (pages 153-155; PDF page 50-52).
[53] Tomatis, L. 2002. The IARC monographs program: changing attitudes towards public health. Int J Occup Environ Health 8(2): 144-52.
[54] Melnick, RL. 2002. The IARC evaluation of di(2-ethylhexyl)phthalate (DEHP): a flawed decision based on an untested hypothesis. Int J Occup Environ Health 8(3): 284-6.
[55] Metrick, M and Marias, AJ (1977). 28-day oral toxicity study with FC-143 in albino rats. Final report. Report prepared for 3M, St. Paul, MN by Industrial Bio-Test Laboratories. Study No. 8532-10654, 3M Reference No. T-1742CoC, Lot 269., Reviewed in US EPA administrative record number AR226-1079.
[56] Perrone, CE., Shao, L and Williams, GM. 1998. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 150(2): 277-86.
[57] Huff, J. 2002. IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer. Int J Occup Environ Health 8(3): 249-70.
[58] Sass, J. 2002. Lead IARC towards compliance with WHO/IARC Declaration of Interests (DOI) policy. Int J Occup Environ Health 8(3): 277-8.
[59] Baines, CJ. 2003. Transparency at the International Agency for Research on Cancer (IARC). Lancet 361(9359): 781-2.
[60] Kleihues, P. 2003. Transparency at the International Agency for Research on Cancer (IARC). Lancet 361(9359): 781.
[61] Burton, A. 2003. Is industry influencing IARC to downgrade carcinogens? Lancet Oncol 4(1): 4.
[62] No authors listed. 2003. Transparency at IARC. Lancet 361(9353): 189.
[63] Cimini, A., Cristiano, L., Bernardo, A., Farioli-Vecchioli, S., Stefanini, S and Ceru, MP. 2000. Presence and inducibility of peroxisomes in a human glioblastoma cell line. Biochim Biophys Acta 1474(3): 397-409.
[64] Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, XY., Moller, G., Nelson, BD and DePierre, JW. 2002. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int Immunopharmacol 2(2-3): 389-97.
[65] Yang, Q., Xie, Y., Alexson, SE., Nelson, BD and DePierre, JW. 2002. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem Pharmacol 63(10): 1893-900.
[66] Yang, Q., Xie, Y and Depierre, JW. 2000. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin Exp Immunol 122(2): 219-26.
[67] Yang, Q., Xie, Y., Eriksson, AM., Nelson, BD and DePierre, JW. 2001. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem Pharmacol 62(8): 1133-40.
[68] Liu, RC., Hahn, C and Hurtt, ME. 1996. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam Appl Toxicol 30(1): 102-8.
[69] Berthiaume, J and Wallace, KB. 2002. Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol Lett 129(1-2): 23-32.
[70] Haughom, B and Spydevold, O. 1992. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta 1128(1): 65-72.
[71] Van Rafelghem, M., Andersen, ME., Bruner, R and Mattie, D. 1982. Comparative toxicity of perfluoro-n-decanoic acid in rats and hamsters. Toxicologist 2: 148.
[72] George, ME and Andersen, ME. 1986. Toxic effects of nonadecafluoro-n-decanoic acid in rats. Toxicol Appl Pharmacol 85(2): 169-80.
[73] Kelling, CK., Van Rafelghem, MJ., Menahan, LA and Peterson, RE. 1987. Effects of perfluorodecanoic acid on hepatic indices of thyroid status in the rat. Biochem Pharmacol 36(8): 1337-44.
[74] Van Rafelghem, MJ., Vanden Heuvel, JP., Menahan, LA and Peterson, RE. 1988. Perfluorodecanoic acid and lipid metabolism in the rat. Lipids 23(7): 671-8.
[75] Gutshall, DM., Pilcher, GD and Langley, AE. 1988. Effect of thyroxine supplementation on the response to perfluoro-n- decanoic acid (PFDA) in rats. J Toxicol Environ Health 24(4): 491-8.
[76] Harris, MW., Uraih, LC and Birnbaum, LS. 1989. Acute toxicity of perfluorodecanoic acid in C57BL/6 mice differs from 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam Appl Toxicol 13(4): 723-36.
[77] Bookstaff, RC., Moore, RW., Ingall, GB and Peterson, RE. 1990. Androgenic deficiency in male rats treated with perfluorodecanoic acid. Toxicol Appl Pharmacol 104(2): 322-33.
[78] Davis, JW, 2nd., Vanden Heuvel, JP and Peterson, RE. 1991. Effects of perfluorodecanoic acid on de novo fatty acid and cholesterol synthesis in the rat. Lipids 26(10): 857-9.
[79] Nelson, DL., Frazier, DE, Jr.., Ericson, JE., Tarr, MJ and Mathes, LE. 1992. The effects of perfluorodecanoic acid (PFDA) on humoral, cellular, and innate immunity in Fischer 344 rats. Immunopharmacol Immunotoxicol 14(4): 925-38.
[80] Environmental Protection Agency (EPA). 2002. Annex of robust study Summaries from the revised draft hazard assessment of perfluorooctanoic acid and its salts, November 4, 2002. U.S. EPA Administrative Record AR226-1137.
|